Natco Pharma Ltd Share Price

Can GLP-1 drugs change India’s productivity story?

A drug can change more than a patient’s weight. It can change how often someone misses work. A recent Danish study of Ozempic users found that long-term sick leave fell after treatment, while employment itself did not meaningfully increase. The important lesson: better health does not automatically translate into more jobs or higher income—but it may help people stay healthier and more consistently at work. Now India is running a much bigger real-world experiment. Semaglutide’s key Indian patent expired in March 2026, opening the market to a wave of cheaper generic versions. Companies including Sun Pharma, Dr. Reddy’s Laboratories, Zydus Lifesciences, Lupin, Alkem, Torrent Pharma and Natco Pharma have entered or developed products in this space. For investors, the interesting question isn't simply: “Who will sell the most GLP-1 drugs?” It is: Who can convert the GLP-1 opportunity into sustainable volumes, margins and market share? Sun Pharma

| Dr. Reddy’s Laboratories | Zydus Lifesciences | Lupin | Alkem Laboratories | Torrent Pharmaceuticals | Natco Pharma This is not a prediction that all will benefit equally. Competition, pricing pressure, regulatory approvals, manufacturing capacity and patient persistence could decide the winners. Healthcare breakthroughs create investment opportunities, but investors must separate market growth from individual company earnings and sustainable competitive advantage.

See More

Natco Pharma: USFDA Issues Form 483 With Four Observations

has received a Form FDA 483 containing four observations following a USFDA inspection at its Finished Dosage Form (FDF) manufacturing facility in Visakhapatnam, Andhra Pradesh. The observations were issued by the USFDA at the conclusion of the inspection, highlighting areas that require the company’s attention and corrective action. Natco Pharma is expected to submit its response to the regulator and undertake appropriate corrective and preventive actions (CAPA) to address the observations. A Form 483 is issued when USFDA investigators identify conditions or practices that may not fully comply with applicable regulatory requirements. However, the issuance of a Form 483 does not represent a final determination of non-compliance by the USFDA. For investors, the key focus will now be on the nature of the four observations, the company’s response and the subsequent regulatory outcome. Any further action by the USFDA or impact on the facility’s operations could influence investor sentiment toward the stock. At this stage, the development represents a regulatory compliance issue that warrants monitoring, with the final impact depending on how the observations are addressed and resolved.

See More

Natco Pharma Targets Double-Digit Domestic Growth; Eyes Agri Export Potential

is targeting double-digit growth in its domestic business. In the agri business (Crop Health Sciences), the company plans to tap export market potential over the next few years. The focus remains on strengthening the base business while exploring opportunities in international markets for its agri portfolio to drive long-term growth. **Top stocks in the pharmaceuticals industry:** Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla.

See More

One Drug Just Wiped Out 44% of Natco Pharma's Revenue. Here's a Concept Worth Knowing.

reported Q1 FY27 revenue of ₹735.2 crore, down 44.7% year-on-year. Net profit fell 57% to ₹206.5 crore. The cause: weak sales of lenalidomide, its generic cancer drug, previously a major international revenue driver. The segment breakdown tells the real story. Domestic formulations actually grew, from ₹107 crore to ₹136.4 crore. API business grew too. The entire collapse came from international formulations, which fell from ₹1,120.9 crore to ₹477.1 crore, over 55% down in that segment alone. This is revenue concentration risk. Generic drug makers often get a temporary exclusivity window to sell a drug before competitors enter and pricing collapses. During that window, revenue can be extraordinary. Once it ends, sales can fall off a cliff almost overnight, which is what appears to have happened here. The lesson generalizes well. Any company where a large share of revenue depends on one product or one temporary advantage carries this same risk, even if the rest of the business is healthy. Natco's domestic and API segments both grew, proof the company isn't broken, but concentration in one drug made the headline look far worse than the underlying business. The takeaway. When one product drives an outsized share of revenue, that strength eventually becomes a vulnerability. Worth checking concentration before assuming a strong quarter repeats.

See More

Update for investors of

is currently trading at Rs. 829.25, up by 3.90 points or 0.47% from its previous closing of Rs. 825.35 on the BSE. The scrip opened at Rs. 834.60 and has touched a high and low of Rs. 837.55 and Rs. 828.80 respectively. So far 1666 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1064.70 on 21-Jul-2025 and a 52 week low of Rs. 635.30 on 23-Mar-2026. Last one week high and low of the scrip stood at Rs. 855.70 and Rs. 813.65 respectively. The current market cap of the company is Rs. 16413.02 crore. The promoters holding in the company stood at 69.87%, while Institutions and Non-Institutions held 20.12% and 10.01% respectively. Alembic Pharmaceuticals’ partner NATCO Pharma (NATCO) has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Olaparib Tablets, 100 mg and 150 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lynparza Tablets, 100 mg and 150 mg, of AstraZeneca Pharmaceuticals LP (AstraZeneca) for the indication in the approved labelling. The company will distribute the product in the U.S., and its partner NATCO will manufacture Olaparib Tablets, 100 mg and 150 mg. The Para IV litigation is on-going. Olaparib Tablets, 100 mg and 150 mg, have an estimated market size of around $1.4 billion in the U.S. for twelve months ending March 2026, according to IQVIA. The company has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA. Alembic Pharmaceuticals is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.

See More